Status:
TERMINATED
COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Myocardial Infarction, Acute
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
This study evaluates the benefit of colchicine on induced denervation after myocardial infarction. Patients who have suffered a documented De Novo myocardial infarction and completed a revascularizati...
Detailed Description
COLD-MI study aims to explore colchicine's impact on myocardial denervation following reperfused acute myocardial infarction. Acute myocardial infarction is the leading cause of heart failure (HF). It...
Eligibility Criteria
Inclusion
- Age from 18 to 80 year old
- Hospitalization within 12 hours of onset of acute chest pain
- Patient must have suffered a documented acute myocardial infarction
- Coronary occlusion on initial angiography (culprit artery with aTIMI (Thrombolysis in Myocardial Infarction) flow 1 or 0)
- Patient eligible for a revascularization procedure by PTCA (Percutaneous transluminal coronary angioplasty)
Exclusion
- Patients with a history of myocardial infarction prior to the current episode
- Patient in cardiogenic shock or with hemodynamic instability
- Patients with severe hepatic or renal dysfunction (GFR ≤30 mL/min)
- Pregnant women or women of childbearing age without contraception
- Treatment with a potent CYP3A4 inhibitor or a P-glycoprotein inhibitor in patients with renal or hepatic impairement
- Association with macrolides (except spiramycin)
- Association with pristinamycin
Key Trial Info
Start Date :
December 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 24 2022
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04420624
Start Date
December 4 2020
End Date
May 24 2022
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UH Montpellier
Montpellier, France, 34090